{
    "nct_id": "NCT02749617",
    "official_title": "A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Patients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group\n* Patients in whom a LEN-DEX-based treatment regimen is indicated\n* Adult patients ≥ 19 years of age who are able to freely provide informed consent\n\nExclusion Criteria:\n\n* Concomitant antiplatelet or anticoagulant use\n* Calculated creatinine clearance \\< 30 mL/min by Cockcroft-Gault formula\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 times upper limit of normal (ULN)\n* Total bilirubin \\> 2 x ULN\n* Thrombocytopenia \\< 50 x 10 gigalitres (Gl)\n* High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time \\> 1.5 x ULN\n* Body weight \\<50 or \\>120 kg\n* Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors\n* Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug\n* Dexamethasone use within last 3 months\n* Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding\n* Life expectancy less than 3 months\n* Inability to swallow or issues with malabsorption\n* Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion\n\nsex: ALL\n\nminimumAge: 19 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Patients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group\n* Patients in whom a LEN-DEX-based treatment regimen is indicated\n* Adult patients ≥ 19 years of age who are able to freely provide informed consent",
        "exclusion": "* Concomitant antiplatelet or anticoagulant use\n* Calculated creatinine clearance < 30 mL/min by Cockcroft-Gault formula\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times upper limit of normal (ULN)\n* Total bilirubin > 2 x ULN\n* Thrombocytopenia < 50 x 10 gigalitres (Gl)\n* High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time > 1.5 x ULN\n* Body weight <50 or >120 kg\n* Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors\n* Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug\n* Dexamethasone use within last 3 months\n* Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding\n* Life expectancy less than 3 months\n* Inability to swallow or issues with malabsorption\n* Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion"
    }
}